Imu Biosciences

Series-A
imubiosciences.com Biotech & Healthcare London, United Kingdom Founded 2021 51-100
Total Funding $67.7M
Latest Round $53M Series-A
Last Announced Jun 1, 2026
Investors 8 Backers
Decision Makers 6 Verified

About Imu Biosciences

Unlocking the potential of the immune system. IMU's cutting-edge platform decodes complex immune challenges to drive breakthroughs and better health outcomes.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters London, United Kingdom
Year Founded 2021
Team Size 51-100
Tracked Since Sep 29, 2026

Web & Domain Identity

Official Website imubiosciences.com
Domain Registered Date Aug 5, 2022

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Raised $53,000,000 · Series-A

    fundraisingfox.com

  2. Capital Raise

    Raised $14,660,200 · Series-A

  3. Milestone

    Website domain registered

    imubiosciences.com

  4. Milestone

    Company founded

    London, United Kingdom

Investors & Backers

8
Beaumont Capital
British Business Bank
COREangels
Expa
IQ Capital
Life Extension Ventures
Meltwind Advisory
Molten Ventures

Funding History

2 Rounds
Series-A · Jun 1, 2026
Series-A · Jan 24, 2024
$14,660,200 Source

Founders & Leadership

5

Adam Laing

Co-founder & Chief Scientific Officer

Work email & phone locked Unlock →

John Baker

CEO

Work email & phone locked Unlock →

Mario Cantero MBA

Co-founder & Chief Operating Officer

Work email & phone locked Unlock →

Thomas Hayday

Co-founder & Chief Research Officer

Work email & phone locked Unlock →

Timothy Haines

Non Executive Chair

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts